非瓣膜性心房颤动相关急性缺血性卒中患者的早期与延迟抗凝治疗
Early versus delayed anticoagulation treatment for people with non-valvular atrial fibrillation-related acute ischaemic stroke.
作者信息
Zhang Xiaodan, Ng Timothy Kar Yip, Yang Yu, Sit Brian Hon Man, Jian Xiaoyu, Zhang Yilin, Li Qianyun, Rainer Timothy Hudson
机构信息
Department of Emergency Medicine, The University of Hong Kong, Hong Kong, China.
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China.
出版信息
Cochrane Database Syst Rev. 2025 Jan 8;1(1):CD016045. doi: 10.1002/14651858.CD016045.
Abstract
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the benefits and risks of early versus late initiation of oral anticoagulation (vitamin K antagonists or NOACs) in people with non-valvular atrial fibrillation-related ischaemic stroke.
摘要
这是一项Cochrane系统评价（干预措施）的方案。目标如下：评估在非瓣膜性心房颤动相关性缺血性卒中患者中，早期与晚期开始口服抗凝治疗（维生素K拮抗剂或新型口服抗凝药）的获益与风险。
相似文献
1
Early versus delayed anticoagulation treatment for people with non-valvular atrial fibrillation-related acute ischaemic stroke.非瓣膜性心房颤动相关急性缺血性卒中患者的早期与延迟抗凝治疗
Cochrane Database Syst Rev. 2025 Jan 8;1(1):CD016045. doi: 10.1002/14651858.CD016045.
2
Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): statistical analysis plan for a randomised controlled trial.急性缺血性卒中合并心房颤动后抗凝治疗的最佳时机（OPTIMAS）：一项随机对照试验的统计分析计划
Trials. 2025 Feb 19;26(1):58. doi: 10.1186/s13063-025-08761-6.
3
Early vs later non-vitamin K antagonist oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation: A meta-analysis and systematic review of randomized trials.急性缺血性卒中合并心房颤动患者早期与晚期使用非维生素K拮抗剂口服抗凝剂的疗效比较：一项随机试验的荟萃分析与系统评价
Heart Rhythm. 2025 Mar;22(3):629-636. doi: 10.1016/j.hrthm.2024.12.008. Epub 2024 Dec 11.
4
Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy.非瓣膜性心房颤动患者行经皮冠状动脉介入治疗后发生卒中和脑出血的风险：比较双联与三联抗栓治疗的随机对照试验的系统评价和荟萃分析。
J Stroke Cerebrovasc Dis. 2021 Apr;30(4):105654. doi: 10.1016/j.jstrokecerebrovasdis.2021.105654. Epub 2021 Feb 10.
5
Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation.近期缺血性脑卒中合并心房颤动患者抗凝治疗的时机。
Lancet Neurol. 2019 Jan;18(1):117-126. doi: 10.1016/S1474-4422(18)30356-9. Epub 2018 Nov 8.
6
Net Benefit of Early Anticoagulation for Stroke With Atrial Fibrillation: Post Hoc Analysis of the ELAN Randomized Clinical Trial.早期抗凝治疗心房颤动相关性卒中的净效益：ELAN随机临床试验的事后分析
JAMA Netw Open. 2025 Jan 2;8(1):e2456307. doi: 10.1001/jamanetworkopen.2024.56307.
7
Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.直接凝血酶抑制剂与维生素K拮抗剂用于预防非瓣膜性心房颤动患者的脑栓塞或全身性栓塞
Cochrane Database Syst Rev. 2014 Mar 27;2014(3):CD009893. doi: 10.1002/14651858.CD009893.pub2.
8
Risk of stroke in patients with prior VKA or DOAC: A population-based real-world registry analysis.先前使用 VKA 或 DOAC 的患者中风风险：基于人群的真实世界登记分析。
Eur Stroke J. 2024 Jun;9(2):418-423. doi: 10.1177/23969873231223876. Epub 2024 Jan 1.
9
Portuguese Observational Study of Ischaemic Stroke in Patients Medicated with Non-Vitamin K Antagonist Oral Anticoagulants.非维生素K拮抗剂口服抗凝剂治疗的缺血性中风患者的葡萄牙观察性研究
Eur Neurol. 2018;79(1-2):108-112. doi: 10.1159/000486755. Epub 2018 Feb 8.
10
Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.基于真实世界证据的非维生素 K 拮抗剂口服抗凝药与维生素 K 拮抗剂口服抗凝药用于非瓣膜性心房颤动患者卒中预防的治疗需要人数。
J Med Econ. 2019 Aug;22(8):760-765. doi: 10.1080/13696998.2019.1606001. Epub 2019 May 3.
本文引用的文献
1
Efficacy and Safety of Direct Oral Anticoagulants for Stroke Prevention in Older Patients With Atrial Fibrillation: A Network Meta-Analysis of Randomized Controlled Trials.直接口服抗凝剂在老年房颤患者卒中预防中的疗效和安全性：一项随机对照试验的网络荟萃分析。
J Am Heart Assoc. 2023 Dec 5;12(23):e030380. doi: 10.1161/JAHA.123.030380. Epub 2023 Nov 28.
2
Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke: The Comparative Effectiveness of Routine Tenecteplase vs Alteplase in Acute Ischemic Stroke (CERTAIN) Collaboration.症状性颅内出血与替奈普酶和阿替普酶治疗急性缺血性脑卒中：急性缺血性脑卒中常规替奈普酶与阿替普酶的比较效果（CERTAIN）协作组。
JAMA Neurol. 2023 Jul 1;80(7):732-738. doi: 10.1001/jamaneurol.2023.1449.
3
Early versus Later Anticoagulation for Stroke with Atrial Fibrillation.早期与晚期抗凝治疗房颤相关性脑卒中。
N Engl J Med. 2023 Jun 29;388(26):2411-2421. doi: 10.1056/NEJMoa2303048. Epub 2023 May 24.
4
Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association.《心脏病与卒中统计数据-2023 更新：美国心脏协会报告》。
Circulation. 2023 Feb 21;147(8):e93-e621. doi: 10.1161/CIR.0000000000001123. Epub 2023 Jan 25.
5
Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study.急性缺血性卒中和心房颤动（TIMING）后早期与延迟非维生素 K 拮抗剂口服抗凝治疗：一项基于登记的随机对照非劣效性研究。
Circulation. 2022 Oct 4;146(14):1056-1066. doi: 10.1161/CIRCULATIONAHA.122.060666. Epub 2022 Sep 6.
6
Optimal timing of anticoagulation after acute ischemic stroke with atrial fibrillation (OPTIMAS): Protocol for a randomized controlled trial.急性缺血性脑卒中合并心房颤动患者抗凝治疗的最佳时机（OPTIMAS）：一项随机对照试验方案。
Int J Stroke. 2022 Jun;17(5):583-589. doi: 10.1177/17474930211057722. Epub 2022 Jan 12.
7
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association.《2021年卒中与短暂性脑缺血发作患者卒中预防指南：美国心脏协会/美国卒中协会指南》
Stroke. 2021 Jul;52(7):e364-e467. doi: 10.1161/STR.0000000000000375. Epub 2021 May 24.
8
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.PRISMA 2020 声明：系统评价报告的更新指南。
BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71.
9
Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.低剂量依度沙班用于高龄房颤患者。
N Engl J Med. 2020 Oct 29;383(18):1735-1745. doi: 10.1056/NEJMoa2012883. Epub 2020 Aug 30.
10
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.2020年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的心房颤动诊断和管理指南：欧洲心脏病学会（ESC）心房颤动诊断和管理特别工作组，由ESC欧洲心律协会（EHRA）特别贡献制定。
Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612.
Zotero 插件